SEARCH

SEARCH BY CITATION

References

  • 1
    Hanisch FG. O-glycosylation of the mucin type. Biol Chem 2001; 382:1439.
  • 2
    Tang CK, Apostolopoulos V. Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines 2008; 7:95162.
  • 3
    Tang CK, Katsara M, Apostolopoulos V. Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines 2008; 7:96375.
  • 4
    Melief CJ. Cancer immunotherapy by dendritic cells. Immunity 2008; 29:37283.
  • 5
    Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220:12950.
  • 6
    Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:47580.
  • 7
    Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195203.
  • 8
    Schwarze SR, Dowdy SF. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharmacol Sci 2000; 21:458.
  • 9
    Shibagaki N, Udey MC. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 2002; 168:2393401.
  • 10
    Wang HY, Fu T, Wang G et al. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest 2002; 109:146370.
  • 11
    Viehl CT, Tanaka Y, Chen T et al. Tat mammaglobin fusion protein transduced dendritic cells stimulate mammaglobin-specific CD4 and CD8 T cells. Breast Cancer Res Treat 2005; 91:2718.
  • 12
    Shibagaki N, Udey MC. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol 2003; 33:85060.
  • 13
    Day EB, Zeng W, Doherty PC, Jackson DC, Kedzierska K, Turner SJ. The context of epitope presentation can influence functional quality of recalled influenza A virus-specific memory CD8+ T cells. J Immunol 2007; 179:218794.
  • 14
    Ciborowski P, Finn OJ. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis. Clin Exp Metastasis 2002; 19:33945.
  • 15
    Barratt-Boyes SM, Vlad A, Finn OJ. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin Cancer Res 1999; 5:191824.
  • 16
    Yamamoto K, Ueno T, Kawaoka T et al. MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer. Anticancer Res 2005; 25:35759.
  • 17
    Domenech N, Henderson RA, Finn OJ. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 1995; 155:476674.
  • 18
    Pietersz GA, Li W, Osinski C, Apostolopoulos V, McKenzie IF. Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. Vaccine 2000; 18:205971.
  • 19
    Kohlgraf KG, Gawron AJ, Higashi M et al. Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunol Immunother 2004; 53:106884.
  • 20
    Heukamp LC, Van Der Burg SH, Drijfhout JW, Melief CJ, Taylor-Papadimitriou J, Offringa R. Identification of three non-VNTR MUC1-derived HLA-A*0201-restricted T-cell epitopes that induce protective anti-tumor immunity in HLA-A2/K(b)-transgenic mice. Int J Cancer 2001; 91:38592.
  • 21
    Apostolopoulos V, Pouniotis DS, Van Maanen PJ et al. Delivery of tumor associated antigens to antigen presenting cells using penetratin induces potent immune responses. Vaccine 2006; 24:3191202.
  • 22
    Ninkovic T, Hanisch FG. O-glycosylated human MUC1 repeats are processed in vitro by immunoproteasomes. J Immunol 2007; 179:23808.
  • 23
    Hiltbold EM, Alter MD, Ciborowski P, Finn OJ. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell Immunol 1999; 194:1439.
  • 24
    Chen D, Xia J, Tanaka Y et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 2003; 109:3007.
  • 25
    Usharauli D, Perez-Diez A, Matzinger P. The JAM test and its daughter P-JAM: simple tests of DNA fragmentation to measure cell death and stasis. Nat Protoc 2006; 1:67282.
  • 26
    Sarkar K, Bose A, Chakraborty K et al. Neem leaf glycoprotein helps to generate carcinoembryonic antigen specific anti-tumor immune responses utilizing macrophage-mediated antigen presentation. Vaccine 2008; 26:435262.
  • 27
    Rughetti A, Pellicciotta I, Biffoni M et al. Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells. J Immunol 2005; 174:776472.
  • 28
    Maraskovsky E, Sjolander S, Drane DP et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ T-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res 2004; 10:287990.
  • 29
    Rieser C, Ramoner R, Holtl L et al. Mature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma. Urol Int 1999; 63:1519.
  • 30
    Morse MA, Nair SK, Mosca PJ et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003; 21:3419.
  • 31
    Homma S, Matai K, Irie M, Ohno T, Kufe D, Toda G. Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma. J Gastroenterol 2003; 38:98994.
  • 32
    O'Rourke MG, Johnson M, Lanagan C et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother 2003; 52:38795.
  • 33
    Kontani K, Taguchi O, Ozaki Y et al. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin. Int J Mol Med 2003; 12:493502.
  • 34
    Agata N, Ahmad R, Kawano T, Raina D, Kharbanda S, Kufe D. MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res 2008; 68:613644.
  • 35
    Ahmad R, Raina D, Trivedi V et al. MUC1 oncoprotein activates the IkappaB kinase beta complex and constitutive NF-kappaB signalling. Nat Cell Biol 2007; 9:141927.
  • 36
    Carraway KL III, Funes M, Workman HC, Sweeney C. Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol 2007; 78:122.
  • 37
    Hanisch FG. Design of a MUC1-based cancer vaccine. Biochem Soc Trans 2005; 33:7058.
  • 38
    Werdelin O, Meldal M, Jensen T. Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proc Natl Acad Sci USA 2002; 99:961113.
  • 39
    Glithero A, Tormo J, Haurum JS et al. Crystal structures of two H-2Db/glycopeptide complexes suggest a molecular basis for CTL cross-reactivity. Immunity 1999; 10:6374.
  • 40
    Speir JA, Abdel-Motal UM, Jondal M, Wilson IA. Crystal structure of an MHC class I presented glycopeptide that generates carbohydrate-specific CTL. Immunity 1999; 10:5161.
  • 41
    Galli-Stampino L, Meinjohanns E, Frische K et al. T-cell recognition of tumor-associated carbohydrates: the nature of the glycan moiety plays a decisive role in determining glycopeptide immunogenicity. Cancer Res 1997; 57:321422.
  • 42
    Heukamp LC, Van Hall T, Ossendorp F et al. Effective immunotherapy of cancer in MUC1-transgenic mice using clonal cytotoxic T lymphocytes directed against an immunodominant MUC1 epitope. J Immunother 2002; 25:4656.
  • 43
    Bae MY, Cho NH, Seong SY. Protective anti-tumor immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli. Clin Exp Immunol 2009; 157:12838.
  • 44
    Morse MA, Lyerly HK, Gilboa E, Thomas E, Nair SK. Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. Cancer Res 1998; 58:29658.
  • 45
    Mukherjee P, Madsen CS, Ginardi AR et al. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J Immunother 2003; 26:4762.